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ABSTRACT
The goal of this thesis project is to isolate and characterize exosomes that express anti-human
CD7 (α-hCD7) single chain variable fragment (scFv), which will be further utilized for T celltargeted gene editing. To reach this goal, exosomes from HEK 293 cells and Jurkat cells were
isolated and characterized with different methodologies. To obtain α-hCD7 scFv-expressing
exosomes, the HEK 293 cells were subjected to transfection of custom-plasmid pDisplay-αhCD7 scFv, and the expression of α-hCD7 scFv on the HEK 293-derived exosomes were then
confirmed by immunogold staining, western blotting, and flow cytometry. To transfect 293 cells,
calcium phosphate transfection was utilized, and the exosomes secreted by these cells were
isolated via sequential ultracentrifugation steps. The exosomes isolated from the transfected cells
were further characterized by a series of methodologies, including western blotting, flow
cytometry, and immunogold labeling, to determine the classic exosome-specific markers along
with the presence of α-hCD7 scFv on the surface of the exosomes. The results suggest the
presence of α-hCD7 scFv on the surface of the transfected 293 cell as well as exosomes when
compared to the untransfected HEK 293 cells and their exosomes. Furthermore, all exosomes
isolated from HEK 293 and Jurkat cells expressed the typical exosome markers, such as CD63
and CD81. We further explored whether exosomes could hybrid with a liposome cargo to carry
the CRISPR-Cas9 plasmid for gene editing. To achieve this, the exosomes isolated from 293
cells were subjected to hybrid formation with liposomes by simply mixing in cold temperatures.
However, no hybrid formation was observed by transmission electronic microscopy (TEM).
Taken together, in this thesis project, we have developed the methodologies to isolate and
characterize the α-hCD7 scFv-expressing exosomes, further enabling the delivery of CRISPRCas9 using exosomes for efficient human T cell-targeted gene editing.
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INTRODUCTION
Genetic engineering
Modern biotechnology through the application of advances made in genetic engineering
has been pivotal in revolutionizing the manipulation and alteration of the characteristics of
'organisms' genomes. Genetic engineering has been extensively applied in a wide array of
organisms, ranging from plants to humans. It has enormous potential for a multitude of
applications across biotechnology, medicine, and basic sciences [1]. The recently emerged gene
editing technologies have provided powerful tools for genetic engineering of 'organisms'
genomes. Holistically, gene editing is the process of producing precise modifications to the
genomes, thus changing the epigenetic markers or transcripts of the organisms. In biosciences
research, these biotechnologies have been utilized to modify, insert, and/or delete DNA
sequences of organisms or cells to dissect specific genes or regulatory elements [2]. Since the
discovery of gene editing technologies, it has been employed in various fields, including gene
therapies, drug developments, and food production, etc. [2].
Gene Editing Technologies
There are multiple gene editing technologies that have been developed in the past two
decades, including zinc-finger nucleases (ZFNs), transcription activator–like effector nucleases
(TALENs), and the RNA-guided clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 (CRISPR-associated protein 9) nuclease system [1]. ZFNs were the first ever
sequence-specific 'designers' nucleases in gene editing technologies that consists of sequencespecific DNA binding domains, namely zinc finger proteins or ZFNs, which is composed of 3–6
Cys2-His2 zinc fingers, and a non-specific DNA cleavage domain derived from FokI
endonucleases [3, 4]. Once two specifically designed ZFNs respectively bind to the double-
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strand DNA, the dimerized FokI endonucleases will be activated, and the DNA will be cleaved
to form a double strand break (DSB). This DSB can be repaired via either non-homologous end
joining mechanism (NHEJ), or DNA recombination once a template is provided, either way, this
will result in an insertion or deletion (Indel), thus disrupting the gene expression. In a clinical
trial, utilizing ZFNs to knockout CCR5 gene, one of the HIV co-receptors, has been conducted
for HIV-1 gene therapy [5, 6]. Similar to ZFNs, TALENs are composed of two domains, namely
DNA-binding domain and C-terminal FokI endonuclease cleavage domain. Specifically, the
DNA binding domain consists of 33-35 amino acids in tandem contained in TALES, which are
from pathogenic bacteria Xanthomonas sp [4, 7]. Unlike ZFNs, where each ZFN module
recognizes three nucleotides, each TALEN module can only recognize one nucleotide.
Therefore, the relatively simple DNA binding rule makes TALENs more easily designed to bind
any unique sequence in the genome [7]. The only limitation for TALENS is that T is required
before the '5'end of the target sequences but can be combated with mutant variants of TALEN Nterminal domains [8]. Overall, these two techniques use DNA-binding domains to bind to the
double-strand DNA, and then the functional endonucleases induce DSBs at specific genomic loci
[1].
CRISPR/Cas9 system
The most recently emerged gene editing technology, the CRISPR/Cas9 system is distinct
from the two aforementioned gene editing mechanisms. Unlike ZFNs or TALENs, which use
protein to bind to DNA, CRISPR/Cas9 system uses a small RNA to bind to one strand of the
target DNA according to Watson-Crick base pairing rule. After binding, the Cas9 protein can
function as nuclease to induce a double strand break, followed by DNA repair via NHEJ or
recombination pathways. Due to the simple design of single guide RNA (sgRNA), CRISPR/Cas9
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system provide a versatile tool for gene editing, and has been widely utilized in a variety of
applications, including the fields of biotechnology, human medicine, biological research,
agriculture etc [2].
CRISPR-Cas systems are derived from the bacteria adaptive immune system, where the
CRISPR-associated genes surrounding the CRISPR sequences encode a series of Cas proteins,
which can function as nucleases to cleave the invading viral DNA (e.g., phage DNA). After each
infection, the CRISPR sequences will be attached to the bacterial genome; thus, the bacteria can
cleave the foreign DNA once the same virus has invaded. Basically, there are six types of
CRISPR-Cas systems that have been identified thus far from a broad spectrum of bacteria
species, while the type II CRISPR-Cas system (e.g., CRISPR-Cas9) has a relatively simple
structure, hence it has been the first CRISPR-Cas system engineered for gene editing[9].
Originally in bacteria, the CRISPR-Cas9 system consists of dual RNA complexed with
endonuclease Cas9 to defend against invading phages and conjugative plasmids by introducing
site-specific double-stranded breaks in the target DNA [10]. Here the dual RNA is comprised of
a small CRISPR RNA (crRNA), which is assembled with a partially complementary trans-acting
RNA (tracrRNA) for processing crRNA. The cas9 protein has been identified from
Streptococcus pyogenes or Staphylococcus aureus and is multifunctional in defending against
pathogens by cutting up DNA in the nuclei. The most important advance in gene editing field is
to artificially engineer the tracrRNA and crRNA to form a guide RNA (gRNA), which can also
guide Cas9 nuclease to target a sequence-specific DNA and introduce a DSB, thus disrupting
gene expression beyond the bacteria species. It is of importance to apply gene editing technology
for a broad application, including food, biotechnology, and medical fields. Notably, in the
CRISPR-Cas9 system, gRNAs guide the multifunctional nuclease protein to the target loci, while
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ZFNs and TALENS require protein domains to recognize the target loci. Essentially, the
CRISPR-Cas9 system can bind to interested target sequences by simply altering the gRNA
sequence to achieve double strand breaks in the precisely designed places [4]. During the
recognition and binding processes, a guide RNA will form a complex with Cas9 protein, and the
guide RNA will recognize and bind to the target DNA by Watson-Crick base-pairing
interactions, which involves a series of conformational changes in functional domains to form a
favorite position for cleavage of both DNA strands. This enables the evaluation of the effect of
sgRNA target DNA mismatches on Cas9 activity [2, 11]. Overall, the composition of CRISPR–
Cas9 system as an RNA-programmable DNA targeting and editing platform is simplified by a
synthetic single-guide RNA (sgRNA) mimicking the natural dual trans-activating CRISPR RNA
(tracrRNA)–CRISPR RNA (crRNA) structure [10]. In our study, SaCas9 was utilized due to its
performance in vivo gene editing and has highly specific genome-wide activity in human cells,
while we used a SaCas9 variant with high gene editing specificity to avoid possible off-target
effects of CRISPR-Cas9 system.
T cell Engineering
T cell engineering has been considered a vital avenue to cure various types of incurable
diseases, such as cancer, HIV, and some autoimmune diseases, because T cells play critical roles
in regulating the whole immune system. Gene engineering of T cells are applicable in areas like
cancers, and it may lead to identifying suitable target antigens, overcoming immunosuppressive
tumor microenvironments, reducing toxicities, and preventing antigen escape [12]. Further
studies can broaden the scope of the applications in extreme diseases like autoimmunity [12].
The most notable progress in T cell engineering is the discovery of chimeric antigen receptor T
cells (CAR-T cells). In the CAR-T cells, T cell receptors (TCR) are modified for antigen
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recognition, thus redirecting the T cells to the specific pathogenic or turmeric antigens.
Generally, the CAR-T cells contain: 1) an extracellular binding domain, which is usually
comprised of a single chain variable fragment of an antibody that can target the specific antigen
(e.g., tumor cells), 2) a T cell activation signaling domain for T cell killing capacity [13].
Theoretically, modifying the binding domain with different specific scFv could be used for
targeting different antigens; therefore, CAR-T cells have been utilized to combat different
lymphomas based on the receptor structure [12, 14]. These modified cells have vigorous activity
against T cells malignancies both in vivo and in vitro [14]. CAR T cells can have modifications
of their CD receptors like CD3, CD28, CD7, CD19 specific entities [12, 14]. T-cells can also be
modified by the CRISPR-Cas9 system as well and combat diseases like HIV-1. In this case,
CD4+ T cells uptake the CRISPR-Cas9 system (e.g., via nucleofection or lentivirus vectors) to
modify either HIV co-receptors or HIV provirus genes, thus providing HIV survival advantage to
the modified CD4+ T cells, or directly eliminating HIV gene from genome of the infected cells
[15, 16]. In addition, T-cell engineering has shown extreme promises in T cell therapy in treating
severe diseases like CMV, EBV, melanoma, and leukemia [17]. T cell engineering has
demonstrated promises in a wide array of applications [18]. However, the above-mentioned T
cell engineering strategies need to modify T cell ex vivo, and then transplant the engineered cells
back to the patients. This T cell therapy strategy makes the therapeutics expensive and difficult
to be utilized to a broad population. Therefore, the development of an efficient T cell in vivo
targeting strategy to deliver CRISPR-Cas9 cargo will make CRISPR-Cas9 more applicable for
various clinical applications. That is also the purpose of our ongoing project. To develop an
appropriate vehicle to deliver CRSIPR/Cas9 for T cell gene editing, we will test for exosomes,
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because exosomes are naturally released from various types of cells, it is theoretically less toxic
and easier to be internalized into T cells.
Extracellular Vesicles: Exosomes
Exosomes are a subtype of extracellular vesicles (EV) that are typically 30-150nm in
diameter and are secreted by all cell types, including T cells. They can be found in plasma, urine,
semen, cerebral spinal fluid, etc., and are enclosed in a single outer membrane. Exosomes have
been used as biomarkers for various diseases [19]. Protein compositions of exosomes are varied
depending on the original sources of the cells/organs. The proteins can be in the cytosol, in
endocytic compartments, or on the plasma membranes. Exosomes lack cell surface proteins such
as Fc receptors in DC-derived exosomes, so they are not just fragments of the plasma membrane
and have independent functions [20]. Exosome derived from different types of cells have distinct
protein makers on the membrane and nucleic acid contents inside the exosomes, that can be used
for identification of cell-type they were derived from. For example, B-cell and T-cell exosomes
have different makers presenting on their membranes, but CD9, CD63, and CD81 are the most
common exosome markers in general [21]. Exosomes have been used in different applications in
biotechnology, like drug delivery or delivery of gRNA and Cas9 proteins to Hela cells [22, 23].
Studies have shown that exosomes can fuse with lipid membranes of artificial liposomes to
create hybrid exosomes; this can be later used as advanced nanocarriers for drug delivery of gene
editing technologies [24]. These studies offer promise in using naturally derived exosomes for in
vivo delivery of CRISPR-Cas9 machinery to T cells.
Holistic Goal of the Project
In this project, the gene editing technology CRISPR-SaCas9, and exosomes will be utilized to
successfully modify the T cell genome via T-cell engineering. Exosomes from Jurkat cells and
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HEK293 cells will be isolated via ultracentrifugation and characterized by antibody binding via
western blot and confocal microscopy, TEM, and flow cytometry20. To achieve T cell targeting
specificity, these cells stated above will be transfected via calcium chloride treatment or
electroporation with an anti-human CD7 (hCD7) scFv gene expressing plasmid, so that the scFv
can amount to the membrane of the exosome for T cell-specific targeting. These exosomes will
then be treated with liposomes to form a membrane hybrid complex where the SaCas9 plasmid
will be co-transfected into these exosomes. Once the hybrids have the SaCas9 plasmid inside
them, they will be used to transfect T cells for gene editing. This exosome-mediated delivery
strategy will be tested both in vitro and in vivo in humanized mouse model, respectively. If time
allowable, humanized mice will be challenged with HIV to test whether CCR5 gene edited T
cells can provide survival advantages against HIV infection when compared with unmodified
humanized mice. The overall schematic of this project design is shown in Fig 1.
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Figure 1 Schematic design of thesis project.
The cartoon showing the project design and the boxed steps are part of this thesis project while the unboxed cartoon shows further downstream applications and
experiments to be performed. Exosomes will be isolated from HEK 293 cells transfected with pDisplay-α-hCD7 scFv. The exosome-liposome hybrid formation
will then be performed by co-incubating the exosome and liposomes and subjected to in vitro T cell binding assays. The overall goal is to load CRISPR-Cas9 geneediting components to these hybrids for efficient gene editing of T cells.

RESEARCH HYPOTHESIS
In this project, the hypothesis is that the exosomes extracted from HEK 293 cells and Jurkat
cells will express exosome markers CD63, CD81, and other exosomal proteins to confirm the
exosomes isolation methodology. Furthermore, HEK 293 cells will be transfected with pDisplayα-hCD7 scFv-GFP, and their exosomes will be isolated and characterized. The isolated
exosomes will express α-hCD7 scFv on the surface of the bilipid layers, which will be confirmed
by flow cytometry, western blotting, and immunogold staining. An exosome-liposome hybrid
will then be formed by mixing the exosomes with liposomes for further downstream testing. In
the later experiments, the α-hCD7 scFv-expressing exosome hybrids will be further tested to
bind to T cells for CRISPR-Cas9 mediated gene editing, including in vitro and in vivo for CCR5knockout and test for HIV protection. Exosome mediated gene delivery is an efficient technique
for T-cell gene editing through the production of exosome-liposome hybrid as a vehicle for gene
delivery to T-cells. To address the stated hypothesis, we will perform following experiments
stated above.
The objectives of this thesis project are to isolate and characterize α-hCD7 scFv -mounted
exosomes from the transfected HEK 293 cells and to confirm exosomal isolation by
characterizing exosomes markers. Moreover, these exosomes generated will be subjected to
hybrid formation by conjugating liposomes and exosomes with different methodologies for
CRISPR-Cas9 delivery.
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MATERIALS AND METHODS
Materials
NEB DH5-alplha E.coli (#C2987I Biolabs), pDisplay α-hCD7 scFV-GFP (Gifted from Yi
Lab, Tyler, Tx, USA), FisherbrandTM Petri Dishes with clear lid (#FB0875712 Fisher Scientific),
14mL Polystene Round Bottom tubes (#352057 Falcon), Nunc DISH 150x20cm (#171663
Thermo Scientific), QIAGEN ® Plasmid Giga Kit (#12191 QIAGEN), Nanodrop 2000
Spectrophotometer (Thermo Scientific), LB Broth Lennox (#BP1427-2 Fisher BioreagentsTM),
0.25% Trypsin-EDTA 1x (#25200-056 Gibco), Dulbecco’s Modification of Eagle’s Medium or
DMEM 1x with 4.5g/L glucose, L-glutamine and sodium pyruvate (#10-0130-CM Corning),
RPMI Medium 1640 1x with L-Glutamine and 25mM HEPES (#22400-089 Gibco) Phosphate
Buffered Saline/ PBS 1x (#SH3025601 Cytiva), Pen Strep (#15140-122 Gibco), Fetal Bovine
Serum (#35-010-CV Corning), HEK 293 cells (#CRL-1573TM ATCC Manassas, Virginia,
USA), Jurkat Cell (ATCC, Manassas, Virginia, USA), 2M Calcium Chloride (#C2510050.0
RPI), Polyethyleneimine Linear Transfection Grade/ PEI 25k (#23966-1 Polyscience, Inc), SW
41 TI rotor (S/N 16U12459 Beckman Coulter), SW 28 Ti Swinging-bucker Rotor (#342204
Beckman Coulter), OptimaTM L-90K Ultracentrifuge (#365672 Beckman Coulter), Ultra-Clear
Centrifuge tubes (#C14293 Beckman Coulter), Polypropylene centrifuge tubes (#326823
Beckman Coulter), Pierce Protease Inhibitor Tables (#A32963 ThermoFisher), Nalgene 0.1µM
PES sterile filter (#565-0010 ThermoFisher), Pierce BCA protein assay Kit (#23227
Thermofisher), Pierce RIPA Buffer (#89900 ThermoScientific), Mini-PROTEAN TGX StainFree Precast Gel (#4568084 Bio-Rad), Trans-blot turbo RTA transfer kit PVDF (#1704272 BioRad), Trans-Blot Turbo Transfer System (Bio-Rad), SuperSignalTM West Pico PLUS
Chemiluminescent Substrate (#34580 ThermoScientic), Dry Milk Powder (#M17200-1000.0

11

RPI), ChemiDocTM Imaging System (Bio-Rad), 4x Laemmli Sample Buffer non-reducing
(#1610747 Bio-Rad), Low Protein Binding Microcentrifuge Tubes 2mL (#88379
ThemoScientific), CD81 (5A6) mouse monoclonal IgG (#SC-23962 Santa Cruz), m-IgGk BPHRP conjugated (#516102 Santa Cruz), CD63 mouse monoclonal IgG (MX-49,12.5) (SC-5275
Santa Cruz), FITC anti-human CD63 Ab (FC) clone H5C6 (#353005 Biolegend), Gt anti-MS
IgG (H+L) Secondary Antibody, HRP Conjugate, (#31430 Invitrogen), Alix (1A12) mouse
monoclonal IgG (SC #53540 Santa Cruz), goat Alpha rabbit IgG HRP conjugated (#AB97051
AbCam), Mouse IgG antibody secondary (#516102 Santa Cruz), Beta actin: (# 4967, Cell
Signaling Technology), HRP anti-HA.11 Epitope Tag (# 901519 BioLegend), Exosome-human
CD63 isolation/defection reagent (from cell culture media) Invitrogen, 3ml (#10606D),
Ultracomp eBeads Plus Compensation beads (#01-333-42 Invitrogen), PE antihuman CD81
Mouse IgG1,k (#349506 Biolegend), ISOTYPE - PE mouse IgG1,k (# 400112 Biolegend), APC
- anti - HA.11 epitope Mouse IgG1,K (#901524 Biolegends), ISOTYPE - APC mouse IgG1, K
Ctrl (# 400142 Biolegends), FITC Anti-human CD63 Clone H5C6 (#353005 Biolegend),
ISOTYPE -FITC mouse control IgG1,K (#400108 Biolegend), FACS buffer: 3mM EDTA +
0.5% BSA/PBS, Running buffer: Tris-MOPS-SDS Running Buffer (# M00138, GenScript).
pDisplay-αhCD7-scFV plasmid preparation, transformation, isolation, and analysis
pDisplay-αhCD7 scFv was acquired from Dr. Guohua 'Yi's Lab (The University of Texas at
Tyler Health Science Center). For transformation of plasmid, the competent E.coli DH5-alplha
competent cells (NEB) was used and prepared using 'Biolab's manufactures protocols.
Competent E. coli was mixed with 100 ng of plasmid DNA and subjected to heat shock
treatment at 42 ºC, 30 sec for transformation. After transformation, bacteria were grown
overnight by shaking at 200 rpm at 37ºC in LB broth supplemented with 100 µg/mL of
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ampicillin, then transferred into 4L volumetric flask with LB broth with 100 µg/mL of ampicillin
and incubated overnight at 37ºC with shaking. QIAGEN giga prep kit was used to extract
plasmid from plasmid-transformed DH5-alplha E.coli. Manufacturing protocol was followed as
per instructions to make a large-scale of plasmid DNA.
Preparing HEK 293 and Jurkat cells and cell culturing
HEK293 and Jurkat cells were used for this project. Complete RPMI-1640 and complete
DMEM media (containing 10% FBS and 1% Penicillin/Streptomycin Solution (PEST)) were
used for Jurkat cells and HEK293 cells, respectively. Exosomes depleted FBS were utilized
when exosomes from cells were isolated. Furthermore, to isolate exosomes, 75% of confluent
cells were washed with PBS at least one time and cultured with complete media supplemented
with exosome depleted FBS. The heat-inactivated FBS was depleted from any nanoparticles
using ultracentrifugation at 100,000xg, at 4 °C for 16 hours.
Transfection of HEK 293 cells
The medium of 70% confluent HEK 293 cells was changed into the medium without
antibiotics prior to transfection. Cells were transfected with CaCl2 treatment and plasmid pDisplay-α-hCD7 scFv and incubated at 37°C and 5% CO2. Medium was changed into complete
DMEM containing 5% FBS and 1% PEST after 6-8 hour of incubation. Calcium Phosphate
transfection was followed as described elsewhere [25]. Another transfection method,
polyethyleneimine (PEI), was also performed according to the reference [26]. Each 150 cm2 dish
was transfected with 100µg of pDisplay- α-hCD7 scFv plasmid. At day 2 post-transfection, the
cell culture medium was changed into the one with exosomes depleted FBS after washing the
cells with PBS, and the cells were incubated at 37°C and 5% CO2 for 48 hours prior to medium
collection for exosomes isolation.
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Exosome Isolation and BCA Assay
Cell culture medium was collected and subjected to differential centrifugation, including 300
g for 5 min, 2500 g for 30 min at 4 °C, and 10,000 g for 30 min at 4 °C. The supernatant was
passed through 0.1 um vacuum filters. After that, the culture medium was spun by
ultracentrifugation with rotor SW-28 (Beckman Coulter) at 110,000 g, at 4 °C for 2 hours. The
exosomal pellet was resuspended with filtered PBS and washed at another 110,000 g, at 4 °C for
2 hours using rotor SW-41T. The exosomes were then resuspended with filtered PBS and
protease inhibitor. The protein concentration of the isolated exosomes was determined using
BCA assay as per manufacturing instructions. The exosome enriched samples were sent out for
transmission electron microscopy and nanoparticle tracking analysis (NTA) to characterize their
shape, number, and size distribution.
Western Blotting Analysis
Cell lysates from untransfected and transfected 293 cells were prepared using Pierce RIPA
Buffer based on manufacturing protocols. Western blot was conducted to visualize CD81, CD63,
CD7, Alix. Beta-actin was also included as a loading control. The Western blot running samples
were un-transfected and transfected cells lysate as well as their exosomes. Mini-PROTEAN
TGX Stain-Free Precast Gel was used, and gel running parameters were based on Bio-Rad
manufacture protocol. Proteins were then transferred into PVDF membranes using Trans-Blot
Turbo Transfer System (Bio-Rad) following 'manufacturer's protocol. The instrument was set up
with 20 volts, 1.8 amps for 10 mins. Membranes were blocked with 5% skimmed milk dissolved
in PBS containing 0.05% Tween 20 (PBST) for 1 hours while shaking at room temperature.
After removing the blocking solution, the membrane was incubated with a primary antibody
against different markers in PBST at 4°C overnight on a shaker. CD81 and CD63 antibodies
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were diluted 1:400 each, HA.11 antibody for α-CD7 scFv detection was diluted to 1:5000, Alix
antibody was diluted to 1:200, and Beta-actin was diluted 1:1000.
Membranes were washed thrice for 5 min each with PBST/TBST on the rotator at room
temperature. Then the CD81 and CD63 primary antibody-incubated membranes were further
incubated with secondary antibody m-IgG BP-HRP at 1:3000 in TBST for one hour at room
temperature. However, the secondary antibody for beta-actin was goat α-rabbit IgG HRP
conjugated at 1:5000 dilution, and the secondary antibody for Alix was mouse IgG antibody
diluted at 1:3000. After three washes, a secondary antibody was added and incubated. After
thrice of washes, the SuperSignalTM West Pico PLUS Chemiluminescent was added to the
membranes at a ratio of 1:1 for 5 minutes at room temperature, avoiding light. The membranes
were exposed to and imaged using ChemiDocTM Imaging System.
Flow Cytometry Analysis
Exosome-human CD63 isolation/detection Dynabeads reagent was resuspended by vortexing
for 30 sec and 20 µl or 2x106 magnetic beads transferred into a 2mL low protein binding tube.
Magnetic beads were washed with 200 µl isolation buffer (PBS with 0.1% BSA, 0.2µM filtered)
and mixed by pipetting up and down slowly. Tubes were placed on a magnet for 1 min, and the
supernatant was discarded. The tubes were then removed, and 95 µl of isolation buffer and 5 µl
of exosomes were added for a final volume of 100 µl and mixed well. All tubes were then
incubated overnight with mixing at 4ºC. The next day, each tube was shortly spun for 3 seconds
to collect samples from the bottom of the tube. Bead-bound exosomes were washed with 300 µl
isolation buffer and mixed gently via pipetting; they were then placed onto a magnet for one
minute, and the supernatant was discarded. Exosomes were washed again following the same
parameters above and then resuspended with 100 µl of isolation buffer to be prepared for
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antibody staining. For staining of exosomes, 1µl of each fluorescent-conjugated antibody was
added into tubes containing beads-bound exosomes. The utilized fluorophores were CD81-PE,
Ha.11 CD7-APC, CD63-FITC. Isotype controls were also included. The isotype controls
included APC-conjugated anti-mouse IgG1, FITC-conjugated anti-mouse IgG1, and PEconjugated anti-mouse IgG1. Three independent experiments were done using exosomes from
un-transfected cells and one experiment for exosomes from transfected cells. Compensation was
carried out using Ultracomp eBeads Plus Compensation Beads. The tubes were placed on a
shaker and shook at 1000 RPM with protection from light at room temperature for one hour.
After incubation, the beads-bound exosomes were washed with 300 µl isolation buffer and
mixed gently. Tubes were placed on a magnet for 1 min, and the supernatant was removed.
Exosomes were washed again following the same parameters above. Finally, beads-bound
exosomes were resuspended with isolation buffer. Analysis was done on Attune NxT acoustic
focusing machine (life technologies).
Cells were stained for CD63, CD81, and α-hCD7 scFv expression using CD81-PE, Ha.11 APC, CD63-FITC. Isotype controls for cell staining were Isotype - APC mouse IgG1Ctrl,
Isotype -FITC mouse IgG1Ctrl, and PE mouse IgG1 Ctrl. Flow cytometry cell staining, the
method described by Kevin Holmes et al. [27] was used for CD81, CD63, and CD7 staining and
isotype controls.
Immunogold Staining, NTA analysis, and Cryogenic-TEM of Exosomes
Cryo-TEM was performed by the Structural Biology Laboratory at UT Southwestern Medical
Center (Dallas, Texas, USA) using their protocols. Immunogold staining and NTA analysis was
performed by Alpha Nano Tech (Research Triangle, North Carolina, USA) based on their
protocol.
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Exosome-Liposome Hybrid Synthesis
Exosomes and liposomes hybrids were composed based on previous research [22, 23].
Exosomes from Jurkat cells and Lipofectamine 2000 as liposomes were mixed at 1:1 ratio and
incubated overnight at 4ºC and sent out for imaging.
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RESULTS
Transfection of HEK 293 Cells
HEK 293 cells were transfected with pDisplay-α-hCD7 scFv plasmid (Fig 2.) using two
methods for comparison, polyethyleneimine and calcium phosphate. The pDisplay-α-hCD7 scFv
plasmid contains the VH domain and VL domain of the α-hCD7 antibody, both of which are
connected via a (GGGGS)3 linker. It also contains an HA Tag and a Myc Tag for expression
confirmation. Moreover, it has a PDGFRβ transmembrane domain at the '3' end, thus the
expressed α-hCD7 scFv is able to mount to the membrane surface for ""Display"" (or targeting).
In addition, it has both GFP and Puromycin markers for selection. After polyethyleneimine
transfection, 293 cells showed the highest GFP expression on days 4 and 5, indicating successful
transfection. However, GFP expression decreased from day 6 onwards (Fig. 3A). Therefore, day
4 of transfection using the calcium phosphate method was used as the primary method for
exosome samples in this project.
Characterization of CD63, CD81 in HEK 293 cells and their exosomes
To isolate exosome populations, sequential centrifugation was used due to its simplicity and
low cost. The isolated exosomes were subjected to negative staining, immunogold staining of
CD63 and CD81. HEK 293-derived exosomes are shown to be bound with CD63 and CD81specific gold nanoparticle-labeled antibodies by negative staining, indicating that the exosomespecific markers, CD63 and CD81, are presented on the surface of the exosomes. (Fig 4A, top
panel, red arrows). Negative and immunogold staining of Jurkat cell-derived exosomes were also
performed to characterize the isolated exosomes. Similarly, Jurkat cells-derived exosomes also
showed successful CD81 and CD63 staining, observed by transmission electron microscopy
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Figure 2. pDisplay- αhCD7 scFv Plasmid map and the schematic of α-hCD7 scFv construct
α-hCD7 scFv gene were cloned into the chosen region of the pDISPLAY plasmid. This coding sequence includes the elements that are necessary for expression of
α-hCD7 scFv and presenting the protein on the membranes of cells/exosomes. The construct includes CMV promoter, IgK leader Sequence., HA Tag, α-hCD7 Ab
VH domain, (GGGGS) x3 linker, α-hCD7 VL domain, Myc tag, and PDGFR-beta transmembrane domainGFP or Purimycin gene can be used for selection of
positively-transfected cells.
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Figure 3. Transfection of HEK 293 Cells
(A) Transfection of HEK 293 cells by polyethyleneimine method and seven-day timeline of GFP expression were shown here. (B) Transfection of HEK 293 cells
using calcium phosphate method with Day 4 and Day 5 GFP pictures with and without fluorescence.
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Figure 4. Characterization of Exosomes and Cells
(A)Negative staining of 293 and Jurkat cells via CRYO-EM and TEM. Immunogold staining was performed to detect CD63 and CD81 expression in both cell linederived exosomes. (B) Western blotting of CD63, CD81, Alix, and Beta actin expression in 293 cells and their exosomes. (C) Frequency of CD81+ and CD63+ in
293 cells and exosomes. (D) Size distribution of 293 exosomes isolated via the ultracentrifuged method. (E) Mean fluorescence Intensity via flow cytometry
analysis of CD81+ and CD63+ 293 cells and their exosomes. (F) Histogram plot analysis of CD81 and CD63 distribution by flow cytometry, the grey (dashed/solid)
curves represent isotype controls. N=3 for transfected cells and untransfected cells. Paired T-test was used to analyze the significance.

(TEM) (Fig 4A, bottom panel, red arrows). The protein concentration of isolated exosomes was
quantified using a BCA assay (data not shown). Sizes of exosomes were average of 146.3nm.
Untransfected and transfected 293 cell lysates and their exosomes were characterized with
western blotting for further validation of the exosome markers. As shown in Fig 4B, cell lysates
and exosomes showed expression of CD63, CD81, and Alix. Exosomes samples also showed
weaker expression when compared to the cell lysate; nonetheless, the exosome-specific markers
were still detected by the relatively faint bands. Western blotting was normalized based on
concentration of 15µg for each sample. Beta actin has been used for gel loading control because
its expression level is usually not influenced by various cell treatment.
Frequency and Mean fluorescence intensity (MFI) of CD81 and CD63 in 293 cells and their
exosomes were characterized by flow cytometry. Both untransfected and transfected showed a
high frequency of CD81+ expression with 98.2% and 99%, respectively. Moreover, CD63
expression was lower in both untransfected and transfected 293 cells which were ~2.3% and
~7%, respectively. Both isolated exosomes derived from untransfected, and transfected cells
showed high expression of CD81 with both <80% (Fig 4C). Isolated exosomes were further
characterized by NTA analysis for size distribution (Fig 4D), And the result showed an average
size of the exosome isolate from untransfected 293 cells was 146.3 nm.
To further explore the exosome marker expression on the HEK 293 cells and their exosomes,
MFI and histogram plots (Fig 4E-F) were created via flow cytometry after gating on the CD81+
and CD63+ cells and exosomes (Supp Fig. 5-7). MFI of CD81 cells was ~10,000 units,
suggesting a high-intensity expression of CD81. Only untransfected 293 exosomes were
measured for CD81 MFI, and it showed ~5000 MFI units, a weaker expression when compared
to HEK 293 cells. However, both untransfected and transfected cells had low MFI values with
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CD63 expression (Fig 4E.). Histogram plots were created for CD81 on untransfected and
transfected cells and the exosomes isolated from them, and CD63 on 293 cells. Both
untransfected and transfected cells had a high-intensity CD81 expression, as both CD81 peaks
are far-right from the peak of the isotype control. All cells-derived exosomes also showed
significantly positive CD81 expression as they all showed distinct peaks from the isotype control
(Fig. 4F, the first three histograms). CD63 on 293 cells showed a slight shift from the isotype
control peak and had low expression (Fig. 4F, the last histogram).
Taken together, all the data described above demonstrated that the exosomes isolated using
sequential ultracentrifugation from these cell lines express the typical exosome markers and has
a homogenous size distribution.
Characterization of α-hCD7 scFv in HEK 293 cells and their exosomes
HEK 293 cells transfected with and without p-Display- α-hCD7 scFv were characterized by
frequency expression, histogram plot via flow cytometry, immunogold staining, and western
blotting analyses (Fig 5). The untransfected 293 cells had a near background level of α-hCD7 scFv
expression, while the transfected 293 cells showed ~15% expression of α-hCD7 scFv determined
by HA.11 CD7 antibody tagged for flow cytometry. The MFI values were acquired for α-hCD7
scFv expression of both cell types (Supplementary Fig. 3). Untransfected cells had a lower MFI
compared to transfected cells (Fig. 5A). The fluorescent intensity of fluorophore APC or
allophycocyanin but there was some background on the untransfected cells resulting in fluorescent
intensity. Finally, α-hCD7 scFv expression was analyzed using exosomes isolated from
untransfected and transfected cells. Untransfected cells-derived exosomes showed nothing
compared to ~80% of α-hCD7 scFv expression on exosomes isolated from the pDisplay-α-hCD7
scFv transfected cells. Expression levels were acquired from layout and gating shown in
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Supplementary Fig. 1, 2, and 4. Gating strategy was determined by size of the cells or exosomes
and by the singlets.
Histogram plots were produced to validate α-hCD7 scFv expression in 293 cell types and their
exosomes. As shown in Fig. 5B, the top panel represent α-hCD7 scFv expression of three repeated
experiments using untransfected HEK 293 cells and compared to the isotype control. There is no
change or shift of the peaks on these cells. However, transfected cells showed some level of α-
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Figure 5. Characterization of α-hCD7 scFv expression in HEK 293 Cells and their Exosomes.
(A) Frequency and MFI of α-hCD7 scFv expression in untransfected and transfected 293 cells with their exosomes. (B) Histogram plot analysis of α-hCD7 scFv
expression by flow cytometry, the grey (dashed) curves represent isotype controls. (C) Immunogold staining of exosomes isolated from transfected 293 cells to
determine α-hCD7 scFv positive exosomes. (D) Western blotting of untrasnfected, transfected 293 cells and their exosomes for confirmation of α-hCD7 scFv
expression. N=3 for untransfected cells and their exosomes, and trasnfected cells only. Paired T-test was used to determine significance.

hCD7 scFv expression, as shown in the middle panel of Fig 5B. Interestingly, distinct from either
the untransfected or transfected cells, the exosomes derived from the transfected cells showed a
nearly separate peak from the ones of the cells, demonstrating a high-level of α-hCD7 scFv
expression (Bottom panel of Fig. 5B).
Immunogold staining was further performed using exosomes isolated from transfected 293
cells. HA tag-specific antibody was used to detect α-hCD7 scFv expression, labeled with gold
nanoparticles for visibility in TEM. This immunogold staining facilitates distinguishing exosome
populations that had a positive α-hCD7 scFv expression on the surface (Fig 5C red arrow). Western
blotting analysis was also performed to further confirm α-hCD7 scFv expression in different cell
lysates and their derived exosomes (Fig 5D). Untransfected 293 cells and their exosomes did not
show any bands or expression. As expected, the transfected 293 cells and their exosomes showed
a clear band for α-hCD7 scFv expression. Samples were normalized based on UT Southwestern’s
protocol.
Overall, this set of experiments demonstrated that both the pDisplay-α-hCD7 scFv transfected
cells and the exosomes derived from them had a successful expression of α-hCD7 scFv.
Exosome-liposome Hybrid Formation
Exosomes transfected from Jurkat cells isolated from supernatant at 70% confluency by
sequential ultracentrifugation and 0.1µM filtration. To engineer hybrids, a simple mixing and
incubation method was employed to fuse the membranes of exosomes and liposomes to form the
hybrids [24]. Exosomes and liposomes (made by Lipofectamine 2000) were mixed together and
incubated overnight at 4°C. After overnight incubation, the hybrid mixture was subjected to TEM.
As shown in Fig 6, no hybrid structure was observed, indicating that the simple mixing and
incubation method to form an exosome-liposome hybrid will not be able to facilitate the CRISPR-
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Cas9 machinery loading. Liposomes are recognized by the size as liposomes are much larger than
exosomes isolated from Jurkat Cells.
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Figure 6. Exosome-Liposome Hybrid Formation
Exosomes and Liposomes were mixed at 1:1 ration and incubated at 4°C, then the TEM images were obtained.

DISCUSSION
Exosomes are promising cell-derived nanovesicles for drug or mRNA delivery because of
their roles in the intercellular transportation of biomolecules [28]. As such, we postulated that
exosomes could play a role in transporting CRISPR-Cas9 for potential therapeutics because of
their specificity to types of cells or tissues for targeted delivery [24, 28]. To increase the T cell
targeting specificity, we mounted an α-hCD7 scFv on the surface of exosomes, enabling the
CRISPR-Cas9 cargo-packaged exosomes direct to T cells for efficient in vivo gene editing. If
successful, these antibody-mediated exosomes for delivery of gene editing machinery to target
cells may open a new avenue for in vivo gene editing applications, including a potential HIV
functional cure. In this thesis study, we attempted to established the methodology to anchor an αhCD7 scFv to the exosome. As a first step for this goal, we have also isolated and wellcharacterized the α-hCD7 scFv exosomes derived from both HEK 293 cells and Jurkat cells, thus
paving the way of utilizing these exosomes for downstream gene editing applications.
Exosomes were isolated using the ultracentrifugation method from two different cells lines
and pulled after centrifugation at 100,000g for 2 hours prior to validation Average size of the
obtained exosome fraction was 140 nm, notably larger than expected 40-100nm exosome
vesicles. This is likely due to the presence of larger vesicles as described previously [29]. This
can be explained that there were some contaminations of larger vesicles and protein aggregated
because of their buoyancy. To counteract this, exosomes should have been floating on a density
gradient during the ultracentrifugation process to exploit their buoyant characteristics and
remove debris as protein aggerates from the exosomal preparation. This also remains true in our
isolation characterization, suggesting that the density gradient method should be pursued in the
future because exosomes in density gradients while ultracentrifugation shows a homogenous
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appearance in size distribution [29]. Alternatively, the size exclusion chromatography may also
help obtain a homogenous exosome population, as suggested by other research groups [30, 31].
As expected, our isolated exosomes demonstrated positive expression of CD81 and CD63 and
showed similar sizes of exosomes characterized [20]. This validated the methodology using
ultracentrifugation method to isolate exosome populations after sequential centrifugation [20,
32]. Furthermore, flow cytometry and western blotting analysis revealed expression of CD81 and
CD63, which further confirmed the quality of exosome populations. In addition, Cryo-EM and
TEM analyses suggested there were other vesicles and protein aggerated captures with this
method, resulting in uneven size distribution. From previous studies, the most widely adopted
method of using differential centrifugation combined with ultracentrifugation may damage
isolated extracellular vesicles, leading to lower quality isolation and potential impact of practical
studies [33]. Given that this damage will need a downstream functional study to characterize, we
cannot make such a conclusion at this time.
HEK 293 cells were transfected with pDisplay-α-hCD7-scFv plasmid using the calcium
phosphate method and showed significant GFP expression, suggesting a successful transfection.
This plasmid contained sequences of VH and VL regions of the α-hCD7 full chain antibody, also
includes a PDGFRβ transmembrane domain, which ensures the expression of α-hCD7 scFv and
mounting it on the surface of exosomes for T cell targeting. With the expression of α-hCD7 scFv
on the surface, we postulated that the exosome will be endocytosed into T cells by the receptormediated endocytosis after binding with the T cell receptor CD7 [34], and followed by the
release of the CRISPR-Cas9 cargo from the exosomes. It is also noted that we chose CD7 as a T
cell receptor target because the CD7 is a pan-T cell molecule that is specifically expressed on T
cells (and a small portion of NK cells) [14]. More importantly, not like CD3 antibody, the
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involvement of CD7 via an CD7 antibody does not extensively activate the T cells [35]. In our
study, the transfected cells and exosomes showed high expression of α-hCD7 scFv using various
detection methods, such as flow cytometry, Western blot, as well as immunogold attaining/TEM,
ensuring the success of the downstream work of CD7 receptor binding and release of CRISPRCas9 machinery for efficient gene editing.
Exosomes isolated from Jurkat cells were subjected to hybrid formation by mixing with
liposomes and incubation overnight at 4ºC. After observing the images taken by TEM, no
exosomes-liposome hybrid was found. Some speculations may be inferred for the inability of this
hybrid. In the natural mechanisms to defend against pathogens and diseases, barriers play a vital
role for safeguarding the vesicle or cell. This helps prevent death and provide integrity of the
body. As such, the membranes are the frontiers of this protection mechanism to maintain the
intact structure of the cells and the substructure, such as vesicles [36]. Therefore, the existed
exosome membranes will not be easily fused with the foreign lipid structures, and the
mechanisms of using the above-attempted methods of forming such hybrid structure are still
unknown [37]. Nevertheless, other methods to form exosome-liposome hybrid, such as
sonication, freeze-thawing, extrusion, and the alike, have been proposed [37]. The field of
hybridization of extracellular vesicles, especially exosomes, are novel and challenging at this
point. However, if exosome hybrid were formed, this concept would lead to a larger cargo space
for a potentially successful CRISPR-Cas9 delivery [24]. This would also enable the hybrids to
specifically target T cells for many clinical applications, such as HIV gene therapy and cancer
immunotherapy.
In summary, exosomes derived from HEK 293 and Jurkat cells were isolated via sequential
ultracentrifugation and characterized using different biotechnological techniques. To validate the
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exosomes for expression of typical exosome markers, immunogold staining, western blotting
analysis, and flow cytometry were performed for CD81 marker using CD63+ beads. The results
all suggested that the isolated exosomes presented CD63 and CD81 markers. Furthermore, HEK
293 cells were transfected with a pDisplay- α-hCD7 scFv and showed high GFP expression, and
their exosomes were also isolated via sequential ultracentrifugation. The same methodologies
were performed to determine α-hCD7 scFv expression from transfected HEK 293 cells-derived
exosomes. The results suggested that α-hCD7 scFv was present on transfected HEK 293 cells
and their exosomes. Contrastingly, untransfected 293 cells and their exosomes did not present
any α-hCD7 scFv on their surface. Additionally, exosomes from Jurkat cells were subjected for
hybrid formation with liposomes. From simple mixing and overnight 4ºC incubation, the hybrid
did not form but other methodologies are still under pursuit. Taken together, we have obtained
the α-hCD7 scFv-mounted exosomes, which were then well-characterized with typical exosome
markers by a series of methodologies. However, the exosome-liposome hybrid formation has not
been successful so far. Nevertheless, using α-hCD7 scFv-mounted exosomes for specifically
targeting T cells for efficient in vivo gene editing will potentially provide a clinically feasible
avenue to HIV gene therapy and cancer immunotherapy.
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Supplementary Figure 1. Gating Strategy of 293 cells for CD81, CD63, and CD7 markers.
Gating Strategy to determine live cell population of 293 cells, single cell population, and positive expression of (A)CD81+, (B) CD63+, and (C) CD7.

APPENDIX
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Supplementary Figure 2 Gating Strategy of Exosomes from 293 cells for CD81 and CD7.
Gating Strategy to determine exosome population, single exosome population, and positive expression of (A) CD81 and (B) CD7 on exosomes. Exosomes were
bound with CD63 beads and stained with CD81-PE, Ha.11 (CD7)-APC.
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Supplementary Figure 3. α-hCD7 scfv layout of untransfected and transfected 293 cells
Flow cytometry analysis of CD7 maker using Ha.11 antibody on (A) transfected and (B) untrasnfected 293 cells. (C) Isotype control was used at the lowest most
panel. Data shown are representative of three independent experiments.
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Supplementary Figure 4. α-hCD7 layout of exosomes from untransfected and transfected 293 cells
Flow cytometry analysis of CD7 of exosomes from (A) untransfected and (C) transfected 293 cells. (B) Isotype control was used on beads and determined positive
or negative expression of CD7 on exosome experiments.
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Supplementary Figure 5. CD81 Layout of Exosomes from HEK 293 cells
Flow cytometry analysis of CD81 of exosomes from (A) untransfected and (C) transfected 293 cells. (B) Isotype control was used on beads and determined positive
or negative expression of CD81 on exosome experiments.
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Supplementary Figure 6. CD81 Layout of Untransfected and transfected 293 cells
Flow cytometry analysis of CD81 on (A) transfected and (B) untransfected 293 cells. (C) Isotype control was used at the lowest panel. Data shown are representative
of three independent experiments.
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Supplementary Figure 7. CD63 Layout of Untransfected and transfected 293 cells
Flow cytometry analysis of CD81 on (A) transfected and (B) untransfected 293 cells. (C) Isotype control was used at the lowest panel. Data shown are representative
of three independent experiments.
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